Please check your internet connection and try again.
# Flupentixol and Melitracen
## Overview
Flupentixol and melitracen is a fixed-dose combination product containing a thioxanthene antipsychotic (flupentixol) and a tricyclic antidepressant (melitracen). It functions as an anxiolytic, antidepressant, and antipsychotic agent.
## Primary Indications
Treatment of mild to moderate anxiety, depression, and apathy; psychosomatic disorders; and depressive neurosis.
## Adult Dosing
* **Initial Dose:** Usually 1 tablet (0.5 mg flupentixol / 10 mg melitracen) twice daily (morning and noon).
* **Maintenance:** 1 tablet daily (morning).
* **Maximum Dose:** 4 tablets daily. Avoid evening doses due to the potential for insomnia caused by the stimulating effect of flupentixol.
## Pediatric Dosing
* **Safety/Efficacy:** Not established. Use is generally not recommended in children or adolescents.
## Dose Adjustments
* **Hepatic/Renal Impairment:** No specific guidelines; use with caution. Reduced starting doses are recommended in elderly patients.
## Contraindications
* Hypersensitivity to either component.
* Recent myocardial infarction and stages of heart block.
* Acute alcohol, barbiturate, or opioid poisoning.
* Circulatory collapse, blood dyscrasias, or coma.
* Concomitant use of MAO inhibitors (requires a 14-day washout period).
## Adverse Effects
* **Common:** Dry mouth, insomnia, agitation, dizziness, tremor, and constipation.
* **Serious:** Extrapyramidal symptoms (dystonia, parkinsonism, akathisia), tachycardia, QT prolongation, and neuroleptic malignant syndrome (NMS).
## Key Drug Interactions
* **MAO Inhibitors:** Risk of hypertensive crisis or serotonin syndrome.
* **CNS Depressants:** Enhanced sedation with alcohol, opioids, or benzodiazepines.
* **Antihypertensives:** May antagonize the effect of guanethidine and similar agents.
* **QT Prolonging Agents:** Increased risk of cardiac arrhythmias if combined with other agents that prolong the QT interval.
## Monitoring
* **Cardiac:** Baseline and periodic ECG, especially in patients with pre-existing heart disease or risks for QT prolongation.
* **Neurological:** Monitor for signs of extrapyramidal symptoms or NMS.
* **Psychiatric:** Monitor closely for increased suicidal ideation, particularly during the initiation of therapy or after dose changes.
## Clinical Pearls
* **Timing:** Administer in the morning to prevent daytime restlessness or nocturnal insomnia.
* **Withdrawal:** Do not discontinue abruptly; taper gradually to avoid withdrawal symptoms (e.g., nausea, headache, irritability).
* **Regulatory Status:** This combination product is not approved by the U.S. FDA and is unavailable in many Western countries due to safety profile concerns regarding the combination of a neuroleptic and a TCA. Always confirm local drug availability and regulatory status.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice varies by region and institution. Always verify current prescribing information, local clinical guidelines, and contraindications via official package inserts or verified pharmacopeia before prescribing or administering medication.
